» Articles » PMID: 36479080

Bile-volatile Organic Compounds in the Diagnostics of Pancreatic Cancer and Biliary Obstruction: A Prospective Proof-of-concept Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Dec 8
PMID 36479080
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Detection of volatile organic compounds (VOCs) from bodily fluids with field asymmetric waveform ion mobility spectrometry (FAIMS) and related methods has been studied in various settings. Preliminary results suggest that it is possible to detect prostate, colorectal, ovarian and pancreatic cancer from urine samples. In this study, our primary aim was to differentiate pancreatic cancer from pancreatitis and benign tumours of the pancreas by using bile samples obtained during endoscopic retrograde cholangiopancreatography (ERCP). Secondarily, we aimed to differentiate all pancreatic region malignancies from all other kinds of benign causes of biliary obstruction.

Methods: A bile sample was successfully aspirated from 94 patients during ERCP in Tampere University Hospital. Hospital and patient records were prospectively followed up for at least two years after ERCP. Bile samples were analysed using a Lonestar chemical analyser (Owlstone, UK) using an ATLAS sampling system and a split-flow box. Diagnoses and corresponding data from the analyses were matched and divided into two subcategories for comparison. Statistical analysis was performed using linear discriminant analysis, support vector machines, and 5-fold cross-validation.

Results: Pancreatic cancers (n=8) were differentiated from benign pancreatic lesions (n=9) with a sensitivity of 100%, specificity of 77.8%, and correct rate of 88%. All pancreatic region cancers (n=19) were differentiated from all other kinds of benign causes of biliary obstruction (n=75) with corresponding values of 21.1%, 94.7%, and 80.7%. The sample size was too small to try to differentiate pancreatic cancers from adjacent cancers.

Conclusion: Analysing bile VOCs using FAIMS shows promising capability in detecting pancreatic cancer and other cancers in the pancreatic area.

Citing Articles

The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.

Barbosa J, Antoniosi Filho N Metabolomics. 2024; 20(5):113.

PMID: 39375265 DOI: 10.1007/s11306-024-02180-5.


A Systematic Review and Meta-Analysis: Volatile Organic Compound Analysis in the Detection of Hepatobiliary and Pancreatic Cancers.

Pelling M, Chandrapalan S, West E, Arasaradnam R Cancers (Basel). 2023; 15(8).

PMID: 37190235 PMC: 10136496. DOI: 10.3390/cancers15082308.

References
1.
Tokar J, Walia R . Diagnostic evaluation of solid pancreatic masses. Curr Gastroenterol Rep. 2013; 15(10):347. DOI: 10.1007/s11894-013-0347-z. View

2.
Duijster J, Franz E, Neefjes J, Mughini-Gras L . Bacterial and Parasitic Pathogens as Risk Factors for Cancers in the Gastrointestinal Tract: A Review of Current Epidemiological Knowledge. Front Microbiol. 2021; 12:790256. PMC: 8692736. DOI: 10.3389/fmicb.2021.790256. View

3.
Bosch S, Berkhout D, Ben Larbi I, de Meij T, de Boer N . Fecal volatile organic compounds for early detection of colorectal cancer: where are we now?. J Cancer Res Clin Oncol. 2018; 145(1):223-234. DOI: 10.1007/s00432-018-2821-3. View

4.
Thomas R, Gharaibeh R, Gauthier J, Beveridge M, Pope J, Guijarro M . Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models. Carcinogenesis. 2018; 39(8):1068-1078. PMC: 6067127. DOI: 10.1093/carcin/bgy073. View

5.
Dumonceau J, Deprez P, Jenssen C, Iglesias-Garcia J, Larghi A, Vanbiervliet G . Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated January 2017. Endoscopy. 2017; 49(7):695-714. DOI: 10.1055/s-0043-109021. View